LYNPARZA for pancreatic cancer treatment obtains FDA-granted orphanage drug designation

pancreatic cancer is a rare, life-threatening disease that accounts for about 3% of all cancers in the United StatesDue to the late onset of symptoms, patients are usually diagnosed only after the cancer progresses to a later stage of the disease or metastasisrecently, AstraZeneca and the U.SMercadoPharmaceutical(OLAPARZA) for pancreatic cancer treatment has been awarded the U.SFDA(the grant of orphan drug designation)Lynparza is currently conducting therapeutic studies for patients with BRCA mutation metastatic pancreatic cancer whose disease has not progressed after first-line platinum chemotherapyLynparza
Lynparza is the world's first (first-in-class) PARP inhibitor and the first targeted treatment that has the potential to prioritize the use of DNA damage response (DDR) pathway defects, such as BRCA mutations, to kill cancer cellsDeveloped and commercialized jointly by AstraZeneca and Mersadon, Lynparza is undergoing a number of clinical
trial(the project was developed for the treatment of more types of cancer patients) in addition to marketed indicationsOctober 2013, Lynparza was certified as an orphan drug for ovarian cancerEarlier in 2018, lynparza was granted orphan drug identification for treatment for fallopian tubes and primary peritonal cancer, following the FDA's expansion in August 2017 to approve maintenance treatment for patients with recurrent epithelial ovaries, fallopian tubes, or primary peritoneal cancerrelated studies
The clinical phase 3 POLO study for pancreatic cancer treatment is currently under way, and the trial will be conducted with a placebo-controlled study of LYNPARZA (300 mg, twice a day) as a maintenance monodotherapy for the efficacy and safety of patients with gBRCAm metastatic pancreatic cancer, where the disease did not progress after first-line platinum chemotherapy145 patients in the trial were randomly given LYNPARZA or placebo at 3:2, with no progressionThe results of the POLO trial are expected to be available in the first half of 2019